Legislative findings and purpose.
Ark. Code Ann. § 20-16-1502
in effect(a) The General Assembly finds that:
(1) The use of abortion-inducing drugs, including the Mifeprex regimen, also known as "RU-486" or "mifepristone", presents significant medical risks, including without limitation incomplete abortion, sepsis or other infections, uterine hemorrhage, blood clots, abdominal pain, fever, vomiting, headache, fatigue, pelvic inflammatory disease, and death;
(2) Medical evidence demonstrates that women who use abortion- inducing drugs risk significantly more complications than those who undergo surgical abortions;
(3) The risk of complications, as well as the failure rate for drug-induced abortions, increases with advancing gestational age;
(4) A woman's ability to provide informed consent depends on the extent to which the woman receives information sufficient to make an informed choice;
(5) The decision to abort "is an important, and often a stressful one, and it is desirable and imperative that it be made with full knowledge of its nature and consequences", as stated in Planned Parenthood v. Danforth, 428 U.S. 52, 67 (1976);
(6) To facilitate reliable scientific studies and research on the safety and efficacy of abortion-inducing drugs, it is essential that the medical and public health communities have access to accurate information on the efficacy of abortion-inducing drugs and resulting complications;
(7) Abortion "recordkeeping and reporting requirements that are reasonably directed to the preservation of maternal health and that properly respect a patient's confidentiality and privacy are permissible", as stated in Planned Parenthood v. Danforth, 428 U.S. 52, 80 (1976); and
(8) "The collection of information with respect to actual patients is a vital element of medical research, and so it cannot be said that the [abortion reporting] requirements serve no purpose other than to make abortions more difficult", as stated in Planned Parenthood v. Casey, 505 U.S. 833, 900-901 (1992).
(b) Based on the findings in subsection (a) of this section, it is the purpose of this subchapter to:
(1) Protect the health and welfare of every woman considering a drug-induced abortion;
(2) Ensure that:
(A) A physician examines a woman before prescribing, administering, or dispensing an abortion-inducing drug; and
(B) A woman considering a drug-induced abortion receives comprehensive information on abortion-inducing drugs;
(3) Reduce "the risk that a woman may elect an abortion, only to discover later, with devastating psychological consequences, that her decision was not fully informed", as stated in Planned Parenthood v. Casey, 505 U.S. 833, 882 (1992); and
(4) Add to the sum of medical and public health knowledge through the compilation of relevant data on drug-induced abortions performed in the state, as well as on all medical complications and maternal deaths resulting from these abortions.
20-16-1503. Definitions.
As used in this subchapter:
(1)(A) “Abortion” means the act of using or prescribing any instrument, medicine, drug, or any other substance, device, or means with the intent to terminate the clinically diagnosable pregnancy of a woman, with knowledge that the termination by those means will with reasonable likelihood cause the death of the unborn child.
(B) An act under subdivision (1)(A) of this section is not an abortion if the act is performed with the intent to:
(i) Save the life or preserve the health of the unborn child;
(ii) Remove a dead unborn child caused by spontaneous abortion;
(iii) Remove an ectopic pregnancy; or
(iv) Treat a maternal disease or illness for which the prescribed drug is indicated;
(2)(A) “Abortion-inducing drug” means a medicine, drug, or any other substance prescribed or dispensed with the intent of terminating the clinically diagnosable pregnancy of a woman, with knowledge that the termination will with reasonable likelihood cause the death of the unborn child.
(B) “Abortion-inducing drugs” includes off-label use of drugs known to have abortion-inducing properties, which are prescribed specifically with the intent of causing an abortion, such as misoprostol, Cytotec, and methotrexate.
(C) This definition does not apply to drugs that may be known to cause an abortion, but which are prescribed for other medical indications such as chemotherapeutic agents or diagnostic drugs.
(D) Use of drugs to induce abortion is also known as a medical, drug-induced, or chemical abortion;
(3) “Adverse event” means an undesirable experience associated with the use of a medical product in a patient, including without limitation an event that causes:
(A) Death;
(B) Threat to life;
(C) Hospitalization;
(D) Disability or permanent damage;
(E) Congenital anomaly or birth defect, or both;
(F) Required intervention to prevent permanent impairment or damage; or
(G) Other serious important medical events, including without limitation:
(i) Allergic bronchospasm requiring treatment in an emergency room;
(ii) Serious blood dyscrasias;
(iii) Seizures or convulsions that do not result in hospitalization; and
(iv) The development of drug dependence or drug abuse;
(4) “Gestational age” means the time that has elapsed since the first day of the woman's last menstrual period;
(5) “Physician” means any person licensed to practice medicine in this state, including medical doctors and doctors of osteopathy; and
(6) “Unborn child” means the offspring of human beings from conception until birth.
20-16-1504. Unlawful distribution of abortion-inducing drug.
(a) Abortion-inducing drugs shall only be prescribed, administered, dispensed, or otherwise provided by a physician following procedures set out in this subchapter.
(b) It is unlawful for any manufacturer, supplier, physician, or any other person to provide any abortion-inducing drug via courier, delivery, or mail service.
(c) Before providing an abortion-inducing drug, the physician prescribing, administering, dispensing, or otherwise providing the abortion- inducing drug shall:
(1) Examine the pregnant woman in person;
(2) Independently verify that an intrauterine pregnancy exists;
(3)(A) Determine the woman's blood type.
(B) If the pregnant woman is Rh negative, the physician shall be able to and offer to administer RhoGAM at the time of the abortion; and
(4) Document in the pregnant woman's medical chart or record the gestational age and intrauterine location of the pregnancy and whether the pregnant woman received treatment for Rh negativity.
(d) A physician prescribing, administering, dispensing, or otherwise providing an abortion-inducing drug shall be credentialed and competent to handle abortion complication management, including emergency transfer, or have a signed agreement with an associated physician who is credentialed to handle abortion complications.
(e) When a signed agreement exists between an associated physician, every pregnant woman to whom a physician prescribes, administers, dispenses, or otherwise provides an abortion-inducing drug shall be given the name and telephone number of the associated physician.
(f) The physician prescribing, administering, dispensing, or otherwise providing an abortion-inducing drug or an agent of the physician shall schedule a follow-up visit for the woman at approximately seven (7) to fourteen (14) days after administration of the abortion-inducing drug to confirm that the pregnancy is completely terminated and to assess the degree of bleeding.
(g) The physician or an agent of the physician shall make all reasonable efforts to ensure that the woman returns for the scheduled follow- up appointment.
(h) A brief description of all efforts made to comply with subsections (f) and (g) of this section, including the date, time, and identification by name of the person making such efforts, shall be included in the woman's medical chart or record.
Source: Arkansas General Assembly, Acts of 2021-2026 (arkleg.state.ar.us)URL: https://arkleg.state.ar.us/Acts/FTPDocument?path=%2FACTS%2F2021R%2FPublic%2F&file=562.pdf&ddBienniumSession=2021%2F2021RFetched: 11/8/2026
